Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride reduces DHT more effectively than finasteride.

Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Finasteride reduces prostate size and PSA levels in young men with hair loss.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.

Stopping finasteride improves sperm quality but not semen volume in young men.

Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.

Finasteride reduces prostate size and symptoms with few side effects.

Osaterone acetate reduces prostate size and enzyme levels in dogs with benign prostatic hyperplasia.

Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.

Finasteride slightly improves prostate symptoms but has minimal difference from placebo.

Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.

Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

Tamsulosin and finasteride improve heart function and circadian rhythm in elderly men with heart failure and prostate issues.

Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.

Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.

Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.

Finasteride helps improve treatment for benign prostatic hyperplasia.

5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.

Finasteride reduces prostate size and PSA levels in young patients.

CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

Finasteride reduces PSA levels by around 40-50% in BPH patients.

The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.

Early hair loss may indicate future prostate issues.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.

Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.